

Digital Commons Annual Report

System Library Services Providence 2021

Digital Commons Report Contributor: Amanda Schwartz, MLIS Digital Asset Librarian

Website: https://digitalcommons.psjhealth.org/


Email: digitalcommons@providence.org

Table of Contents

| Overview (Digital Commons and Expert Gallery Platforms) | 2 |
|---|---|
| Publications by Clinical Institute | |
| Readership Distribution | |
| | |
| PlumX Altmetrics | |
| Regional Research | |
| Noteworthy Projects | 7 |
| nternal Presentations and External Conferences | 8 |


Overview (Digital Commons and Expert Gallery Platforms)

In 2021, Providence Digital Commons maintained steady growth collecting materials and building new collections. Notably, Digital Commons has received increased global usage across 158 countries. Repository usage grew 33.6% from 2020-2021.




Publications by Clinical Institute

Collected publications surpassed the year-end outstanding metric target designated by System Research (1,650) with a year-end total of 1,780 submissions.



| | # of |
|----------------------|------|
| 2021 YTD | Pubs |
| Cancer | 504 |
| Cardiovascular | 273 |
| COVID-19 | 154 |
| Digestive Health | 80 |
| Diversity | 24 |
| Genomics | 70 |
| Kidney and Diabetes | 179 |
| Mental Health | 47 |
| Neurosciences | 219 |
| Orthopedics & Sports | |
| Medicine | 97 |
| Nursing | 214 |
| Women & Children | 128 |
| Other | 211 |



Readership Distribution

Global readership indicates the potential reach and impact of materials held in Digital Commons. 2021 held wide-ranging distribution of readership and interaction. Institutional access, both internal at Providence and from external users, was diverse.




Repository items were accessed by readers from 158 countries around the world. Top 10 countries with interaction:

Top 10 countries by download*

- United States 18,434
- China 3,068
- India 912
- United Kingdom 905
- Canada 791
- Australia 597
- Russian Federation 433
- Netherlands 391
- Germany 376
- Republic of Korea 375

*not all material records in Digital Commons have downloadable content; only 20% of records include downloadable files




Jan - Dec 2021 Downloads 33,806



Jan - Dec 2021 Metadata Page Hits 36,730

PlumX Altmetrics

Digital Commons includes PlumX Metrics*, which allows us to see how users interact with our research items. PlumX collects internal and external data, to display how wide-reaching our research materials are.



The top five highest performing articles in each PlumX metric category were (titles highlighted in green were high-performers in multiple categories):

| Usage (abstract views/downloads/full text views/link outs/plays) | |
|---|-------|
| Digital Health Practices, Social Media Use, and Mental Well-Being Among Teens and Young | 20845 |
| Adults in the U.S. | |
| Minimally Invasive Lung Cancer Surgery Performed by Thoracic Surgeons as Effective as | 12705 |
| <u>Thoracotomy.</u> | |

| Guidelines, Family Choices, and Neonatal Outcomes9269Are you still on the fence about wearing a mask?9269Sex-specific associations of maternal birthweight with offspring birthweight in the Omega study.7437Citations (including clinical and policy citations)3001First Case of 2019 Novel Coronavirus in the United States3001Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial.2766Remdesivir for the Treatment of Covid-19 — Final Report2465Covid-19 in Critically III Patients in the Seattle Region — Case Series1275Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.664Captures (saves/bookmarks)2164Covid-19 in Critically III Patients in the Seattle Region — Case Series2164Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial.1462Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.1241Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
|---|---|
| Sex-specific associations of maternal birthweight with offspring birthweight in the Omega study. Citations (including clinical and policy citations) First Case of 2019 Novel Coronavirus in the United States Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial. Remdesivir for the Treatment of Covid-19 — Final Report Covid-19 in Critically III Patients in the Seattle Region — Case Series Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. Captures (saves/bookmarks) Covid-19 in Critically III Patients in the Seattle Region — Case Series Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU. Conserved cell types with divergent features in human versus mouse cortex. 1103 Mentions (news mentions/blogs/references) Remdesivir for the Treatment of Covid-19 — Final Report First Case of 2019 Novel Coronavirus in the United States | |
| Study.Citations (including clinical and policy citations)First Case of 2019 Novel Coronavirus in the United States3001Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial.2766Remdesivir for the Treatment of Covid-19 — Final Report2465Covid-19 in Critically III Patients in the Seattle Region — Case Series1275Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.664Captures (saves/bookmarks)2164Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial.1462Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.1241Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| Citations (including clinical and policy citations)First Case of 2019 Novel Coronavirus in the United States3001Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial.2766Remdesivir for the Treatment of Covid-19 — Final Report2465Covid-19 in Critically III Patients in the Seattle Region — Case Series1275Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.664Captures (saves/bookmarks)2164Nivolumab in Critically III Patients in the Seattle Region — Case Series2164Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial.1462Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.1241Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| First Case of 2019 Novel Coronavirus in the United States3001Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.2766Remdesivir for the Treatment of Covid-19 — Final Report2465Covid-19 in Critically III Patients in the Seattle Region — Case Series1275Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.664Captures (saves/bookmarks)2164Covid-19 in Critically III Patients in the Seattle Region — Case Series2164Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.1462Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.1241Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open- label, non-comparative, phase 1/2 dose escalation and expansion trial.2766Remdesivir for the Treatment of Covid-19 — Final Report2465Covid-19 in Critically Ill Patients in the Seattle Region — Case Series1275Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.664Captures (saves/bookmarks)2164Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.1462Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.1241Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| label, non-comparative, phase 1/2 dose escalation and expansion trial.Remdesivir for the Treatment of Covid-19 — Final Report2465Covid-19 in Critically III Patients in the Seattle Region — Case Series1275Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.664Captures (saves/bookmarks)2164Covid-19 in Critically III Patients in the Seattle Region — Case Series2164Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial.1462Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.1241Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| Remdesivir for the Treatment of Covid-19 — Final Report2465Covid-19 in Critically III Patients in the Seattle Region — Case Series1275Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.664Captures (saves/bookmarks)2164Covid-19 in Critically III Patients in the Seattle Region — Case Series2164Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial.1462Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.1241Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| Covid-19 in Critically III Patients in the Seattle Region — Case Series1275Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.664Captures (saves/bookmarks)Covid-19 in Critically III Patients in the Seattle Region — Case Series2164Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial.Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.Conserved cell types with divergent features in human versus mouse cortex.Mentions (news mentions/blogs/references)Remdesivir for the Treatment of Covid-19 — Final ReportFirst Case of 2019 Novel Coronavirus in the United States | |
| Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.Captures (saves/bookmarks)664Covid-19 in Critically III Patients in the Seattle Region — Case Series2164Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial.1462Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.1241Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| Captures (saves/bookmarks)Covid-19 in Critically III Patients in the Seattle Region — Case Series2164Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial.1462Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.1241Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| Covid-19 in Critically III Patients in the Seattle Region — Case Series2164Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial.1462Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.1241Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.1462Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.1241Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015First Case of 2019 Novel Coronavirus in the United States840 | |
| label, non-comparative, phase 1/2 dose escalation and expansion trial.Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.1241Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.1241Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| implicates Aβ, tau, immunity and lipid processing.1126Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)840Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| Neonatal Neuroprotection: Bringing Best Practice to the Bedside in the NICU.1126Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references)1015Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| Conserved cell types with divergent features in human versus mouse cortex.1103Mentions (news mentions/blogs/references) | |
| Mentions (news mentions/blogs/references)Remdesivir for the Treatment of Covid-19 — Final Report1015First Case of 2019 Novel Coronavirus in the United States840 | |
| Remdesivir for the Treatment of Covid-19 — Final Report 1015 First Case of 2019 Novel Coronavirus in the United States 840 | |
| First Case of 2019 Novel Coronavirus in the United States 840 | |
| | |
| | |
| <u>Covid-19 in Critically III Patients in the Seattle Region — Case Series</u> | |
| Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, 205 | |
| Genetic, and Clinical Networks by Human Herpesvirus. | |
| Conserved cell types with divergent features in human versus mouse cortex. 115 | |
| Social Media (Facebook count/likes/tweets) | |
| First Case of 2019 Novel Coronavirus in the United States 63424 | 1 |
| Remdesivir for the Treatment of Covid-19 — Final Report 42866 | _ |
| Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. 11688 |) |
| A History of Orthognathic Surgery in North America. 11542 | |
| Utilization of the validated Psoriasis Epidemiology Screening Tool (PEST) to identify signs 11537 | 3 |
| and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis | 3 |
| from the US-based Corrona Psoriasis Registry. | 3 |

^{*}PlumX Metrics only collects all time data, and does not filter metrics by timeframe. All data listed is all time data since the establishment of the Providence Digital Commons (2018-current).

Regional Research

Breakdown of Providence research materials by region.

Numbers may vary from annual total publications based on breakdown of single and shared authorship/multiple authors from different regions within Providence.



^{*}System tagged publications had authors affiliated at the top organizational level, without a more specific region

Noteworthy Projects

In 2021, Digital Commons focused on easing the submission process and created a new, robust system for tracking research by region. Library staff and system research identified a breakdown of regional locations and key-player-locations (institutions within the organization that are frequently affiliated to).

Researchers could also begin submitting materials using the <u>Digital Commons Submission Form</u>, creating a streamlined experience both for users and library staff.

- To create a more organized platform, Digital Commons built special regional collections, research collections, and conference collections, totaling 38 new collections:
 - List of Region and Institution Collections
 - o <u>Swedish Neuroscience Institute</u>

- Swedish Heart and Vascular Institute
- o Swedish Cancer Institute
- o Saint John's Cancer Institute (JWCI)
- o Pacific Neuroscience Institute
- o Center for Outcomes Research and Education (CORE)
- o Oregon Academic Achievement Day, 2021
- o St. Joseph Hospital EBP Conference, 2021

Internal Presentations and External Conferences

Digital Commons statistics and flexible database structure was leveraged in multiple meetings as valuable tools for research and readership tracking and departmental report-outs

Library staff continued system-wide partnerships through outreach and participation in research councils, giving 23 internal presentations and conversations on Digital Commons.

Library Director Heather J. Martin and Digital Asset Librarian Amanda Schwartz presented and published on Digital Commons and Providence research at the 2021 Medical Institutional Repositories in Libraries (MIRL) Symposium:

• <u>Finding Our Stride: A Health System Repository 4 Years In / Providence Patents: Using an</u> Institutional Repository to Promote Technology Transfer